Imunon Inc - Asset Resilience Ratio
Imunon Inc (IMNN) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Imunon Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Imunon Inc's Asset Resilience Ratio has changed over time. See IMNN net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Imunon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IMNN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Imunon Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Imunon Inc Industry Peers by Asset Resilience Ratio
Compare Imunon Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Imunon Inc (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Imunon Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $9.72 Million | -- |
| 2023-12-31 | 44.97% | $9.86 Million | $21.92 Million | -3.36pp |
| 2022-12-31 | 48.33% | $21.25 Million | $43.98 Million | +8.08pp |
| 2021-12-31 | 40.25% | $29.80 Million | $74.05 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $37.53 Million | -- |
| 2019-12-31 | 20.86% | $7.99 Million | $38.28 Million | -9.57pp |
| 2018-12-31 | 30.43% | $14.26 Million | $46.86 Million | +3.65pp |
| 2017-12-31 | 26.78% | $12.72 Million | $47.51 Million | +21.33pp |
| 2016-12-31 | 5.45% | $1.68 Million | $30.85 Million | -16.58pp |
| 2015-12-31 | 22.03% | $10.80 Million | $49.03 Million | -14.22pp |
| 2014-12-31 | 36.24% | $24.17 Million | $66.69 Million | -45.11pp |
| 2013-12-31 | 81.36% | $37.16 Million | $45.67 Million | +49.66pp |
| 2012-12-31 | 31.70% | $8.04 Million | $25.36 Million | +0.59pp |
| 2011-12-31 | 31.11% | $10.16 Million | $32.65 Million | +15.45pp |
| 2010-12-31 | 15.66% | $395.56K | $2.53 Million | -22.80pp |
| 2009-12-31 | 38.47% | $5.70 Million | $14.81 Million | +21.32pp |
| 2008-12-31 | 17.15% | $4.06 Million | $23.69 Million | +9.46pp |
| 2007-12-31 | 7.68% | $3.00 Million | $39.04 Million | -34.58pp |
| 2006-12-31 | 42.26% | $8.00 Million | $18.93 Million | +4.55pp |
| 2005-12-31 | 37.71% | $6.00 Million | $15.91 Million | -20.33pp |
| 2004-12-31 | 58.04% | $9.90 Million | $17.05 Million | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-2… Read more